KeyCorp Issues Positive Forecast for ICU Medical (NASDAQ:ICUI) Stock Price

ICU Medical (NASDAQ:ICUI) had its target price raised by KeyCorp from $187.00 to $189.00 in a report released on Friday, Benzinga reports. The firm presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp‘s price objective suggests a potential upside of 8.10% from the stock’s current price.

A number of other research firms have also commented on ICUI. Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Weiss Ratings raised shares of ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Needham & Company LLC boosted their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. BTIG Research boosted their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Zacks Research downgraded shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $195.20.

ICU Medical Stock Performance

Shares of ICUI stock opened at $174.84 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. ICU Medical has a fifty-two week low of $113.37 and a fifty-two week high of $192.85. The stock has a 50 day moving average price of $162.97 and a two-hundred day moving average price of $149.18. The company has a market capitalization of $4.37 billion, a P/E ratio of 146.95, a PEG ratio of 2.17 and a beta of 0.88.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.30. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The firm had revenue of $556.22 million during the quarter, compared to analyst estimates of $552.03 million. During the same quarter in the prior year, the firm posted $2.03 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Analysts expect that ICU Medical will post 7.22 earnings per share for the current year.

Insiders Place Their Bets

In other ICU Medical news, insider Ben Sousa sold 2,250 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the transaction, the insider directly owned 3,076 shares of the company’s stock, valued at approximately $548,512.32. The trade was a 42.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Virginia Sanzone sold 4,856 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the transaction, the vice president directly owned 14,604 shares in the company, valued at approximately $2,463,548.76. The trade was a 24.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 21,830 shares of company stock valued at $3,905,003 over the last quarter. 2.10% of the stock is owned by company insiders.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Gagnon Securities LLC boosted its position in ICU Medical by 0.8% during the 3rd quarter. Gagnon Securities LLC now owns 29,630 shares of the medical instruments supplier’s stock valued at $4,756,000 after acquiring an additional 230 shares in the last quarter. Maryland State Retirement & Pension System raised its position in shares of ICU Medical by 52.7% in the 3rd quarter. Maryland State Retirement & Pension System now owns 5,549 shares of the medical instruments supplier’s stock worth $891,000 after acquiring an additional 1,914 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of ICU Medical in the 3rd quarter worth approximately $987,000. Illinois Municipal Retirement Fund lifted its stake in shares of ICU Medical by 9.2% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 13,788 shares of the medical instruments supplier’s stock valued at $2,213,000 after purchasing an additional 1,162 shares during the period. Finally, Lido Advisors LLC lifted its stake in shares of ICU Medical by 15.4% in the 3rd quarter. Lido Advisors LLC now owns 3,707 shares of the medical instruments supplier’s stock valued at $595,000 after purchasing an additional 494 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: ICU Medical reported third-quarter earnings of $2.44 per share, above the $2.14 consensus estimate and up from $2.03 a year earlier. Revenue was $556.22 million, also ahead of expectations, and increased 4.4% year over year. ICU Medical Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company reaffirmed fiscal 2026 guidance and said it expects results toward the high end of its previously provided range, signaling confidence in its outlook. ICU Medical Announces Q3 Results and Reaffirms Guidance
• Neutral Sentiment: Despite the earnings beat and reaffirmed guidance, the stock is lower. The articles provided do not point to a clear company-specific reason for the move. ICU Medical Q3 Adjusted Earnings, Revenue Rise

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.